GNMX - Aevi Genomic Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.1700
-0.0091 (-5.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.1791
Open0.1860
Bid0.1058 x 1000
Ask0.0000 x 1000
Day's Range0.1700 - 0.1880
52 Week Range0.1500 - 1.3900
Volume405,544
Avg. Volume1,703,171
Market Cap11.01M
Beta (3Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.3490
Earnings DateMay 11, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.58
Trade prices are not sourced from all markets
  • PR Newswire

    Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody

    Plan to enter Phase 2 in Adult Onset Still's Disease and other serious rare and orphan diseases PHILADELPHIA , Aug. 7, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") ...

  • PR Newswire

    Aevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare Conference

    PHILADELPHIA , Aug. 6, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that Michael F. Cola , President and Chief Executive Officer, will present ...

  • PR Newswire

    Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor

    Entering Phase 2 clinical trials for the treatment of Lymphatic Malformations which include a number of rare and orphan diseases. PHILADELPHIA, July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of Astellas Pharma Inc. ("Astellas") for the worldwide development and commercialization of Astellas' second generation mTORC1/2 inhibitor, ASP7486 (OSI-027). Aevi's initial focus of study with ASP7486 will be for congenital Lymphatic Malformations, which includes a number of rare and orphan diseases.

  • ACCESSWIRE

    These Four Healthcare Stocks are Surging with Potential

    CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NVAX), and Aevi Genomic Medicine Inc (GNMX) are 4 healthcare companies raising the bar on Tuesday.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Zacks Small Cap Research

    GNMX: ASCEND Misses Primary Endpoint: GNMX indicates they are not giving up in AEVI-001

    On January 2nd Aevi (GNMX) announced that ASCEND, the phase II trial evaluating their non-stimulant glutamatergic neuromodulator in pediatric and adolescent subjects with ADHD, failed to meet its primary endpoint of a statistically significant reduction of ADHD-RS at 6 weeks in either Part A (mGluR+ subjects) or Part B (mutation free subjects). As we have consistently stated in our coverage, given the largely positive results of SAGA and enrichment of ASCEND with only patients with mutations to nine select genes in the mGluR network, along with a pediatric weighting, we had expected ASCEND would prove successful. As a reminder about SAGA’s results (see link to our report), it did meet statistical significance on the CGI-I secondary endpoint as well as on the ADHD-RS responder measure (prespecified as decrease of ADHD-RS score of 30% or more, which is considered a clinical response).

  • ACCESSWIRE

    The Next Big Biotech Breakout

    HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...

  • Benzinga

    The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

    Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.

  • PR Newswire

    Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD

    PHILADELPHIA, Jan. 2, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001.  AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.

  • ACCESSWIRE

    4 Pharma Stocks Getting a Boost on Thursday (12/20/18)

    CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.

  • PR Newswire

    Aevi Genomic Medicine to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD

    PHILADELPHIA, Nov. 26, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R. Stulman Professor in Child and Adolescent Psychiatry at Johns Hopkins University.  During the breakfast they will discuss the diagnosis and treatment paradigms in Attention Deficit Hyperactivity Disorder (ADHD).  The breakfast is being held on Thursday, November 29, 2019 at 8:00 AM EST at the National in New York, New York. Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the Company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP).

  • GlobeNewswire

    Detailed Research: Economic Perspectives on Gogo, Aevi Genomic Medicine, PBF Energy, SiteOne Landscape Supply, Douglas Dynamics, and Dine Brands Global — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Zacks Small Cap Research

    GNMX: With ASCEND Enrollment Completed, Read-Out Expected In Q1’19

    Aevi Genomic Medicine (GNMX) reported Q3 financial results and provided a business update. Just two months later, GNMX announced that part ‘B’ (i.e. Also noteworthy is that while the initial plan was for parts A and B to enroll and read-out sequentially, given the rapid enrollment of part B, the expectation is now that top-line data will be announced for both in January.

  • Associated Press

    Aevi Genomic Medicine: 3Q Earnings Snapshot

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 12 cents. The company's shares closed at $1.09. A year ago, they were trading at $1.66. _____ This story was generated ...

  • PR Newswire

    Aevi Genomic Medicine Reports Third Quarter 2018 Financial Results and Provides Business Update

    PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September ...

  • PR Newswire

    Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial

    PHILADELPHIA, Oct. 15, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial.  The ASCEND trial is a genomically-guided study in pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder (ADHD) assessing the safety and efficacy of AEVI-001, a novel, non-stimulant therapy. Part B of the ASCEND trial is studying pediatric and adolescent patients with ADHD without mGluR mutations.